Compare Avantis International Small Cap Value ETF (AVDV) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs BridgeBio Pharma Inc — how do they compare? Avantis International Small Cap Value ETF trades at $109.58, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | BBIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $90.17 |
52-Week Low | $83.89 | $47.29 |
Market Cap | — | $16.61B |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $109.63, up 1.34% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI. The stock has delivered strong returns recently, including a 35% gain highlighted in June 2026 news, and offers a dividend with a payment scheduled for June 2026. However, key valuation ratios such as P/E and P/B are unavailable, limiting fundamental clarity.
The outlook is mixed: technical strength and positive media coverage on international small-cap value performance support upside, but overbought RSI levels and missing financial metrics pose risks. Investors should weigh the ETF's exposure to developed markets outside the U.S. against potential volatility from commodity sectors, as noted in recent analysis.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
